CN Patent

CN120204216A — 用于治疗异位骨化的方法

Assigned to Clementia Pharmaceuticals Inc · Expires 2025-06-27 · 1y expired

What this patent protects

本发明提供了用于治疗异位骨化的方法。本发明的特征在于用于经口施用帕罗伐汀的给药方案和药物配制物。所述给药方案可以在罹患进行性骨化性纤维发育不良的受试者中减少异位骨化、减少暴发的数量和/或降低暴发的严重程度。

USPTO Abstract

本发明提供了用于治疗异位骨化的方法。本发明的特征在于用于经口施用帕罗伐汀的给药方案和药物配制物。所述给药方案可以在罹患进行性骨化性纤维发育不良的受试者中减少异位骨化、减少暴发的数量和/或降低暴发的严重程度。

Drugs covered by this patent

Patent Metadata

Patent number
CN120204216A
Jurisdiction
CN
Classification
—
Expires
2025-06-27
Drug substance claim
No
Drug product claim
No
Assignee
Clementia Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.